Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer

Antonello Veccia, Orazio Caffo, Ugo De Giorgi, Giuseppe Di Lorenzo, Cinzia Ortega, Florinda Scognamiglio, Michele Aieta, Gaetano Facchini, Giovanni Mansueto, Rodolfo Mattioli, Giuseppe Procopio, Vittorina Zagonel, Alessandro D'Angelo, Gilbert Spizzo, Roberto Bortolus, Maddalena Donini, Giovanni Lo Re, Francesco Massari, G. Vicario, Paolo Andrea Zucali & 16 others Daniele Alesini, A. Bonetti, C. Mucciarini, M. Nicodemo, Alfredo Berruti, Lucia Fratino, Michele Lodde, Caterina Messina, A. Perin, Daniele Santini, T. Sava, Marcello Tucci, Umberto Basso, Francesca Maines, Salvatore Luca Burgio, E. Galligioni

Research output: Contribution to journalArticle

Abstract

Aim: To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer. Patients & methods: The multicenter retrospective study was based on a review of the pre-and post-DOC clinical history, DOC treatment and outcomes. Results: We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3-4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival. Conclusion: The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.

Original languageEnglish
Pages (from-to)493-502
Number of pages10
JournalFuture Oncology
Volume12
Issue number4
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

docetaxel
Castration
Prostatic Neoplasms
Drug Therapy
Survival
Multicenter Studies
Disease-Free Survival
Retrospective Studies

Keywords

  • castration-resistant prostate cancer
  • docetaxel
  • elderly
  • geriatric assessment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. / Veccia, Antonello; Caffo, Orazio; De Giorgi, Ugo; Di Lorenzo, Giuseppe; Ortega, Cinzia; Scognamiglio, Florinda; Aieta, Michele; Facchini, Gaetano; Mansueto, Giovanni; Mattioli, Rodolfo; Procopio, Giuseppe; Zagonel, Vittorina; D'Angelo, Alessandro; Spizzo, Gilbert; Bortolus, Roberto; Donini, Maddalena; Lo Re, Giovanni; Massari, Francesco; Vicario, G.; Zucali, Paolo Andrea; Alesini, Daniele; Bonetti, A.; Mucciarini, C.; Nicodemo, M.; Berruti, Alfredo; Fratino, Lucia; Lodde, Michele; Messina, Caterina; Perin, A.; Santini, Daniele; Sava, T.; Tucci, Marcello; Basso, Umberto; Maines, Francesca; Burgio, Salvatore Luca; Galligioni, E.

In: Future Oncology, Vol. 12, No. 4, 01.02.2016, p. 493-502.

Research output: Contribution to journalArticle

Veccia, A, Caffo, O, De Giorgi, U, Di Lorenzo, G, Ortega, C, Scognamiglio, F, Aieta, M, Facchini, G, Mansueto, G, Mattioli, R, Procopio, G, Zagonel, V, D'Angelo, A, Spizzo, G, Bortolus, R, Donini, M, Lo Re, G, Massari, F, Vicario, G, Zucali, PA, Alesini, D, Bonetti, A, Mucciarini, C, Nicodemo, M, Berruti, A, Fratino, L, Lodde, M, Messina, C, Perin, A, Santini, D, Sava, T, Tucci, M, Basso, U, Maines, F, Burgio, SL & Galligioni, E 2016, 'Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer', Future Oncology, vol. 12, no. 4, pp. 493-502. https://doi.org/10.2217/fon.15.302
Veccia, Antonello ; Caffo, Orazio ; De Giorgi, Ugo ; Di Lorenzo, Giuseppe ; Ortega, Cinzia ; Scognamiglio, Florinda ; Aieta, Michele ; Facchini, Gaetano ; Mansueto, Giovanni ; Mattioli, Rodolfo ; Procopio, Giuseppe ; Zagonel, Vittorina ; D'Angelo, Alessandro ; Spizzo, Gilbert ; Bortolus, Roberto ; Donini, Maddalena ; Lo Re, Giovanni ; Massari, Francesco ; Vicario, G. ; Zucali, Paolo Andrea ; Alesini, Daniele ; Bonetti, A. ; Mucciarini, C. ; Nicodemo, M. ; Berruti, Alfredo ; Fratino, Lucia ; Lodde, Michele ; Messina, Caterina ; Perin, A. ; Santini, Daniele ; Sava, T. ; Tucci, Marcello ; Basso, Umberto ; Maines, Francesca ; Burgio, Salvatore Luca ; Galligioni, E. / Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. In: Future Oncology. 2016 ; Vol. 12, No. 4. pp. 493-502.
@article{99cd173fc6f14d4d9a559490d86b5924,
title = "Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer",
abstract = "Aim: To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer. Patients & methods: The multicenter retrospective study was based on a review of the pre-and post-DOC clinical history, DOC treatment and outcomes. Results: We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3-4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival. Conclusion: The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.",
keywords = "castration-resistant prostate cancer, docetaxel, elderly, geriatric assessment",
author = "Antonello Veccia and Orazio Caffo and {De Giorgi}, Ugo and {Di Lorenzo}, Giuseppe and Cinzia Ortega and Florinda Scognamiglio and Michele Aieta and Gaetano Facchini and Giovanni Mansueto and Rodolfo Mattioli and Giuseppe Procopio and Vittorina Zagonel and Alessandro D'Angelo and Gilbert Spizzo and Roberto Bortolus and Maddalena Donini and {Lo Re}, Giovanni and Francesco Massari and G. Vicario and Zucali, {Paolo Andrea} and Daniele Alesini and A. Bonetti and C. Mucciarini and M. Nicodemo and Alfredo Berruti and Lucia Fratino and Michele Lodde and Caterina Messina and A. Perin and Daniele Santini and T. Sava and Marcello Tucci and Umberto Basso and Francesca Maines and Burgio, {Salvatore Luca} and E. Galligioni",
year = "2016",
month = "2",
day = "1",
doi = "10.2217/fon.15.302",
language = "English",
volume = "12",
pages = "493--502",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer

AU - Veccia, Antonello

AU - Caffo, Orazio

AU - De Giorgi, Ugo

AU - Di Lorenzo, Giuseppe

AU - Ortega, Cinzia

AU - Scognamiglio, Florinda

AU - Aieta, Michele

AU - Facchini, Gaetano

AU - Mansueto, Giovanni

AU - Mattioli, Rodolfo

AU - Procopio, Giuseppe

AU - Zagonel, Vittorina

AU - D'Angelo, Alessandro

AU - Spizzo, Gilbert

AU - Bortolus, Roberto

AU - Donini, Maddalena

AU - Lo Re, Giovanni

AU - Massari, Francesco

AU - Vicario, G.

AU - Zucali, Paolo Andrea

AU - Alesini, Daniele

AU - Bonetti, A.

AU - Mucciarini, C.

AU - Nicodemo, M.

AU - Berruti, Alfredo

AU - Fratino, Lucia

AU - Lodde, Michele

AU - Messina, Caterina

AU - Perin, A.

AU - Santini, Daniele

AU - Sava, T.

AU - Tucci, Marcello

AU - Basso, Umberto

AU - Maines, Francesca

AU - Burgio, Salvatore Luca

AU - Galligioni, E.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Aim: To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer. Patients & methods: The multicenter retrospective study was based on a review of the pre-and post-DOC clinical history, DOC treatment and outcomes. Results: We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3-4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival. Conclusion: The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.

AB - Aim: To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer. Patients & methods: The multicenter retrospective study was based on a review of the pre-and post-DOC clinical history, DOC treatment and outcomes. Results: We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3-4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival. Conclusion: The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.

KW - castration-resistant prostate cancer

KW - docetaxel

KW - elderly

KW - geriatric assessment

UR - http://www.scopus.com/inward/record.url?scp=84957695804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957695804&partnerID=8YFLogxK

U2 - 10.2217/fon.15.302

DO - 10.2217/fon.15.302

M3 - Article

VL - 12

SP - 493

EP - 502

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 4

ER -